Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07178743 · ClinicalTrials.gov registry record
Emulation of the PALOMA-2 Trial
A clinical trial of Advanced Breast Cancer, sponsored by Brigham and Women's Hospital.
- Active
- Registry status
- 6,097
- Enrollment target
- 1
- Study location
NCT07178743: Active study of Advanced Breast Cancer, sponsored by Brigham and Women's Hospital.
NCT07178743 is a study of Advanced Breast Cancer that is active but no longer recruiting, run by Brigham and Women's Hospital. The registered enrollment target is 6,097 participants, above the 247-participant average among 28 other Advanced Breast Cancer trials with a reported enrollment target (2368% higher). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07178743, a study of Advanced Breast Cancer, is active but no longer recruiting, sponsored by Brigham and Women's Hospital.
- ACTIVE NOT RECRUITING
- Registry status
- 6,097 participants
- Enrollment target
- 1
- Study location
Study Summary
Investigators are building an empirical evidence base for real world data through large-scale emulation of randomized controlled trials. The investigators' goal is to understand for what types of clinical questions real world data analyses can be conducted with confidence and how to implement such studies.
Primary Outcome
Hazard ratio (95% CI)
Conditions Studied
Interventions
- DRUG Initiation of palbociclib plus letrozole
- DRUG Initiation of letrozole
Study Locations (1)
Massachusetts
- Brigham and Women's Hospital - Boston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 6,097 participants |
| Start Date | 2025-07-14 |
| Est. Completion | 2026-03 |
What the registry record for NCT07178743 still lists
NCT07178743 is an observational study that tracks outcomes without assigning an intervention. Its 6,097 participants enrollment target places it among the larger protocols in the corpus, above the 247-participant average among 28 other Advanced Breast Cancer trials with a reported enrollment target (2368% higher).
The record links to 1 condition, with Advanced Breast Cancer appearing as the primary indexed condition, and to 2 interventions - of which Initiation of palbociclib plus letrozole is the first listed.
NCT07178743 reports a single indexed study location in Massachusetts.
Frequently Asked Questions
What is clinical trial NCT07178743 about?
NCT07178743 is a clinical study titled "Emulation of the PALOMA-2 Trial". Investigators are building an empirical evidence base for real world data through large-scale emulation of randomized controlled trials. The investigators' goal is to understand for what types of clinical questions real world data analyses can be conducted with confidence and how to implement such s...
What is the current status of trial NCT07178743?
This trial is currently active not recruiting. The enrollment target is 6,097 participants. The study started on 2025-07-14. Estimated completion is 2026-03.
What conditions does trial NCT07178743 study?
This clinical trial studies the following conditions: Advanced Breast Cancer.
What interventions are being tested in trial NCT07178743?
The interventions under investigation include: Initiation of palbociclib plus letrozole (DRUG), Initiation of letrozole (DRUG).
Who is sponsoring clinical trial NCT07178743?
This trial is sponsored by Brigham and Women's Hospital, which has 937 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07178743 being conducted?
This trial has 1 study location across Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Advanced Breast Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT07178743's enrollment target sits among peer trials
6,097 1st of 28 higher than 28 of 28 other Advanced Breast Cancer trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Advanced Breast Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Engage Psychosocial Intervention for Cancer Symptoms
RECRUITING · NA
-
Sequencing Antibody Drug Conjugates in ER+/HER2 LOW/ULTRA LOW MBC
RECRUITING · Phase 2
-
Phase 1/2 Study of ETX-636 in Participants With Advanced Solid Tumors
RECRUITING · Phase 1
-
Metarrestin (ML-246) in Subjects With Metastatic Solid Tumors
RECRUITING · Phase 1
-
Open-Label Study of BBO-10203 in Subjects With Advanced Solid Tumors
RECRUITING · Phase 1
-
BGB-43395 Alone or as Part of Combination Therapies in Participants With Breast Cancer and Other Advanced Solid Tumors
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT07166861 · 6,080 participants · NA
Annual Wellness Visits vs GRACE-augmented Annual Wellness Visits For Older Adults With High Needs - Phase 2
- NCT04774159 · 6,150 participants · Phase 3
Low Dose ColchicinE in pAtients With Peripheral Artery DiseasE to Address Residual Vascular Risk
- NCT06304168 · 6,150 participants
Validation of DNA Methylation Markers for Universal and Site-specific Guided Cancer Detection, VANGUARD Study
- NCT05884190 · 6,030 participants · NA
Trauma-informed Approach to Timely Detection and Management of Early Postpartum Hypertension
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI